Core Points - MannKind Corporation held an investor call on November 10, 2025, to discuss a clinical trial update [1] - The call included forward-looking statements regarding MannKind's product candidates, reflecting the company's current perspective on trends and information [2] - Actual results may differ from projections due to various risks and uncertainties, as noted in MannKind's SEC filings [3] Company Information - The call featured Chief Executive Officer Michael Castagna, who provided updates on the company's clinical trials [4]